Context Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
CNTX$0.20+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders’Equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||
| Balance at January 1, 2024 | 15,966,053 | $15,966 | $79,909,644 | $(68,054,590) | $11,871,020 | ||||
| Share-based compensation expense | — | — | 841,867 | — | 841,867 | ||||
| Sale of common stock and prefunded warrants in private placement, net of offering costs of $5,234,020 | 59,032,259 | 59,032 | 94,699,715 | — | 94,758,747 | ||||
| Sale of common stock from ATM facility, net of offering costs of $480,268 | 14,705,882 | 14,706 | 14,505,026 | — | 14,519,732 | ||||
| Net loss | — | — | — | (26,725,104) | (26,725,104) | ||||
| Balance at December 31, 2024 | 89,704,194 | $89,704 | $189,956,252 | $(94,779,694) | $95,266,262 | ||||
| Exercise of pre-funded warrants from private placement | 2,174,983 | 2,175 | (2,175) | — | — | ||||
| Share-based compensation expense | — | — | 1,331,080 | — | 1,331,080 | ||||
| Net loss | — | — | — | (36,123,615) | (36,123,615) | ||||
| Balance at December 31, 2025 | 91,879,177 | $91,879 | $191,285,157 | $(130,903,309) | $60,473,727 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.